COLLEGIUM PHARMACEUTICAL INC (COLL) Stock Price, Forecast & Analysis
NASDAQ:COLL • US19459J1043
COLL Key Statistics, Chart & Performance
The current stock price of COLL is 41.67 USD. In the past month the price decreased by -8.11%. In the past year, price increased by 43.44%.
COLL Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to COLL. When comparing the yearly performance of all stocks, COLL is one of the better performing stocks in the market, outperforming 74.81% of all stocks.
COLL Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to COLL. COLL scores excellent on profitability, but there are some minor concerns on its financial health.
COLL Financial Highlights
Over the last trailing twelve months COLL reported a non-GAAP Earnings per Share(EPS) of 7.46. The EPS increased by 15.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 7.72% | ||
| ROA | 3.64% | ||
| ROE | 21.27% | ||
| Debt/Equity | 2.71 |
COLL Forecast & Estimates
12 analysts have analysed COLL and the average price target is 54.74 USD. This implies a price increase of 31.37% is expected in the next year compared to the current price of 41.67.
For the next year, analysts expect an EPS growth of 8.61% and a revenue growth 3.54% for COLL
COLL Ownership
COLL Latest News, Press Relases and Analysis
COLL Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 31.34 | 966.197B | ||
| JNJ | JOHNSON & JOHNSON | 21.32 | 586.592B | ||
| MRK | MERCK & CO. INC. | 22.88 | 296.105B | ||
| PFE | PFIZER INC | 9.21 | 154.083B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 10.25 | 124.384B | ||
| ZTS | ZOETIS INC | 19.09 | 57.184B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.91 | 26.184B | ||
| VTRS | VIATRIS INC | 5.9 | 17.564B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.25 | 13.013B | ||
| AXSM | AXSOME THERAPEUTICS INC | 200.12 | 8.226B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About COLL
Company Profile
Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. The company is headquartered in Stoughton, Massachusetts and currently employs 357 full-time employees. The company went IPO on 2015-05-07. The firm has developed, licensed, and acquired a portfolio of products for use in the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. Its commercial products include Jornay PM (Jornay), Belbuca, Xtampza ER (Xtampza), Nucynta ER and Nucynta IR (Nucynta Products), and Symproic in the United States. Its Jornay is a central nervous system (CNS) stimulant prescription medicine for the treatment of ADHD. The Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. The Xtampza ER is a pain treatment option designed with abuse deterrent properties. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic.
Company Info
COLLEGIUM PHARMACEUTICAL INC
100 Technology Center Dr
Stoughton MASSACHUSETTS 02072 US
CEO: Joseph Ciaffoni
Employees: 357
Phone: 17817133699
COLLEGIUM PHARMACEUTICAL INC / COLL FAQ
What does COLLEGIUM PHARMACEUTICAL INC do?
Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. The company is headquartered in Stoughton, Massachusetts and currently employs 357 full-time employees. The company went IPO on 2015-05-07. The firm has developed, licensed, and acquired a portfolio of products for use in the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. Its commercial products include Jornay PM (Jornay), Belbuca, Xtampza ER (Xtampza), Nucynta ER and Nucynta IR (Nucynta Products), and Symproic in the United States. Its Jornay is a central nervous system (CNS) stimulant prescription medicine for the treatment of ADHD. The Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. The Xtampza ER is a pain treatment option designed with abuse deterrent properties. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic.
What is the current price of COLL stock?
The current stock price of COLL is 41.67 USD. The price decreased by -5.77% in the last trading session.
Does COLL stock pay dividends?
COLL does not pay a dividend.
How is the ChartMill rating for COLLEGIUM PHARMACEUTICAL INC?
COLL has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Would investing in COLLEGIUM PHARMACEUTICAL INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on COLL.
What is the market capitalization of COLL stock?
COLLEGIUM PHARMACEUTICAL INC (COLL) has a market capitalization of 1.32B USD. This makes COLL a Small Cap stock.
Can you provide the ownership details for COLL stock?
You can find the ownership structure of COLLEGIUM PHARMACEUTICAL INC (COLL) on the Ownership tab.